查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1611101

患者来源的异质骨移植模型市场规模、份额和趋势分析报告：按肿瘤类型、模型类型、最终用途、地区和细分市场预测，2025-2030 年

Patient-derived Xenograft Model Market Size, Share & Trends Analysis Report By Tumor Type (Lung Cancer, Breast Cancer), By Model Type (Mice Model, Rat Model), By End Use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

患者来源的异质骨移植模型市场成长与趋势

2030年，全球患者来源的异质骨移植模型市场规模预计将达到5.053亿美元，预计2025年至2030年复合年增长率为9.64%。日益增加的癌症负担推动了对新治疗方案的需求，以及全球对个人化治疗的强劲需求，将推动产业成长。患者来源的异种移植（PDX）模型在过去十年中获得了认可。该模型通常涉及将源自患者的肿瘤组织引入新鲜的免疫力缺乏小鼠。这些模型可用于临床前测试，以确定有希望的药物反应性和抗药性生物标记，并监测治疗后肿瘤的发展。同时使用多个模型进行协作临床测试的概念（称为「化身模型」）最近受到欢迎，并已扩展到包括 PDX 模型。

此外，PDX 模型也用于多项前瞻性研究，以指导有限数量的观察到存活率改善的患者的治疗方案决策。 COVID-19 大流行对该行业产生了负面影响。它扰乱了临床测试并降低了製药和生物製药公司的生产力。根据 Avantor Sciences 的研究，截至 2020 年 7 月，全球 70% 的临床试验已暂停。儘管出现了新冠肺炎 (COVID-19) 疫情，但癌症患者数量的增加以及製药公司研发活动的增加预计将有助于市场成长。例如，根据 GLOBOCAN 2020 年报告，2020 年将新增 1,930 万癌症病例，约 1,000 万人死亡。受影响的主要癌症是乳癌、肺癌、大肠癌和摄护腺癌。

患者来源的异质骨移植模型市场报告亮点

  • 随着全球乳癌病例不断增加，到 2024 年，乳癌细分市场将占销售额的 31.7%。
  • 例如，女性乳癌预计将新增 230 万例，使其成为发病率最高的疾病，超过肺癌。
  • 2024年，滑鼠模型领域占据市场主导地位。小鼠是异种移植研究中最常用的动物类型，因为它们已经建立了免疫力缺乏品系，具有成本效益且易于处理。
  • 由于製药和生技公司研发活动外包的增加，CRO 和 CDMO 领域在 2024 年占据市场主导地位。
  • 由于对更准确、更可靠的临床前模型推动药物发现和开发的需求不断增加，预计製药和生物製药公司将在 2025 年至 2030 年经历显着增长。
  • 北美患者来源的异质骨移植模型市场在全球市场中占据主导地位，2024年将占44.6%的份额。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章患者来源的异质骨移植模型市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/补充市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 市场分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19 影响分析

第四章患者来源的异质骨移植模型市场：按肿瘤类型的估计和趋势分析

  • 细分仪表板
  • 患者来源的异质骨移植模型的全球市场：肿瘤类型变异分析
  • 2018-2030 年患者来源异质骨移植模型的全球规模和趋势分析（按肿瘤类型）
  • 肺癌
  • 胰臟癌
  • 摄护腺癌
  • 乳癌
  • 其他的

第五章患者来源的异质骨移植模型市场：依模型类型进行估计与趋势分析

  • 细分仪表板
  • 病患衍生异质骨移植模型的全球市场：模型类型的变异分析
  • 2018-2030 年病患来源异质骨移植模型的全球规模与趋势分析（按模型类型）
  • 小鼠模型
  • 大鼠模型

第六章 病人来源的异质骨移植模型市场：最终用途的估计和趋势分析

  • 细分仪表板
  • 病患来源的异质骨移植模型的全球市场：最终用途变异分析
  • 2018-2030 年患者来源异质骨移植模型的全球规模和趋势分析（按最终用途）
  • 製药/生物製药公司
  • 学术研究所
  • CRO 和 CDMO

第七章 病人来源的异质骨移植模型市场：区域、估计与趋势分析

  • 2024 年及 2030 年按地区分類的市场占有率分析
  • 区域市场仪表板
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 公司分类
  • 2024 年企业市场分析
  • 公司简介
    • Charles River Laboratories
    • The Jackson Laboratory
    • Crown Bioscience
    • Altogen Labs
    • Envigo
    • WuXi AppTec
    • Oncodesign
    • Hera Biolabs
    • XenTech
    • Abnova Corp.
Product Code: GVR-4-68040-002-0

Patient-derived Xenograft Model Market Growth & Trends:

The global patient-derived xenograft model market size is expected to reach USD 505.3 million in 2030 and is projected to grow at a CAGR of 9.64% from 2025 to 2030. Growing burden of cancer, which is promoting the demand for new treatment options, along with significant demand for personalized therapies worldwide will boost the growth of the industry. Patient-derived Xenograft (PDX) models have garnered increasing awareness during the past decade. These types are typically characterized by the introduction of fresh immunodeficient mice with patient-derived tumor tissues. These models have been used with efficacy in preclinical studies to identify prospective biomarkers for drug response and resistance, as well as to monitor the development of tumors in therapy response. The concept of a co-clinical study, which involves using several models at once-referred to as "Avatar models"-has recently grown in popularity and has been expanded to incorporate PDX models.

Moreover, PDX models were used in a few prospective trials to direct therapeutic therapy decisions for a limited number of patients with confirmed extended survival. The COVID-19 pandemic had a negative impact on the industry. It disrupted the clinical trials and also reduced the productivity of pharmaceutical & biopharmaceutical companies. According to research by Avantor Sciences, 70% of global clinical trials were disrupted as of July 2020. 369 trials related to oncology had been delayed in the USA alone, central nervous system trials at 223, gastrointestinal trials at 116, and cardiovascular trials at 99. Despite COVID-19, the rising number of cancer cases & increased R&D activities by pharmaceutical companies will contribute to the growth of the market. For instance, as per the GLOBOCAN Report 2020, 19.3 million new cancer cases and almost 10.0 million cancer deaths occurred in 2020. The majorly impacted cancers were breast, lung, colorectal, and prostate cancer.

Patient-derived Xenograft Model Market Report Highlights:

  • The breast cancer segment dominated with 31.7% of the revenue share in 2024 owing to increasing cases of breast cancer globally.
  • For instance, female breast cancer is expected 2.3 million new cases & has surpassed lung cancer as the most prevalent disease diagnosed.
  • The mice model segment dominated the market in 2024. Mice are the most commonly used species for xenograft studies due to their well-established immunodeficient strains, cost-effectiveness, and ease of handling.
  • The CRO and CDMO segment dominated the market in 2024 owing to increasing outsourcing activities by pharmaceutical and biotechnology companies for research and development activities.
  • Pharmaceutical and biopharmaceutical companies are projected to witness considerable growth from 2025 to 2030 owing to the increasing demand for more accurate and reliable preclinical models to advance drug discovery and development.
  • North America patient-derived xenograft model market dominated the global market and accounted for a 44.6% share in 2024.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Tumor Type
    • 1.2.2. Model Type
    • 1.2.3. End Use
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity Flow Analysis
    • 1.6.2. Bottom-up Approach
  • 1.7. List of Secondary Sources
  • 1.8. List of Abbreviations
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Patient-derived Xenograft Model Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growing Burden of Cancer Across the Globe
      • 3.2.1.2. Increasing R&D Investment for Cancer Research
      • 3.2.1.3. Demand for Personalized Therapies Worldwide
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High Cost of Personalized PDX Models
      • 3.2.2.2. Stringent Regulations Towards the Use of Animal Models
  • 3.3. Market Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Patient-derived Xenograft Model Market: Tumor Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Patient-derived Xenograft Model Market; Tumor Type Movement Analysis
  • 4.3. Global Patient-derived Xenograft Model Size & Trend Analysis, by Tumor Type, 2018 to 2030 (USD Million)
  • 4.4. Lung Cancer
    • 4.4.1. Lung cancer market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Pancreatic Cancer
    • 4.5.1. Pancreatic cancer market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Prostate Cancer
    • 4.6.1. Prostate cancer market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Breast Cancer
    • 4.7.1. Breast cancer market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Patient-derived Xenograft Model Market: Model Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Patient-derived Xenograft Model Market; Model Type Movement Analysis
  • 5.3. Global Patient-derived Xenograft Model Size & Trend Analysis, by Model Type, 2018 to 2030 (USD Million)
  • 5.4. Mice Model
    • 5.4.1. Mice model market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Rat Model
    • 5.5.1. Rat model market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Patient-derived Xenograft Model Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Patient-derived Xenograft Model Market; End Use Movement Analysis
  • 6.3. Global Patient-derived Xenograft Model Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 6.4. Pharmaceutical and Biopharmaceutical Companies
    • 6.4.1. Pharmaceutical and biopharmaceutical companies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Academic and Research Institutes
    • 6.5.1. Academic and research institutes market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. CRO's and CDMO's
    • 6.6.1. CRO's and CDMO's market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Patient-derived Xenograft Model Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. North America
    • 7.3.1. North America Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Competitive scenario
      • 7.3.2.3. Regulatory framework
      • 7.3.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Competitive scenario
      • 7.3.3.3. Regulatory framework
      • 7.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.4. Mexico
      • 7.3.4.1. Key country dynamics
      • 7.3.4.2. Competitive scenario
      • 7.3.4.3. Regulatory framework
      • 7.3.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. Europe Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.4.2. UK
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Competitive scenario
      • 7.4.2.3. Regulatory framework
      • 7.4.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. Germany
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Competitive scenario
      • 7.4.3.3. Regulatory framework
      • 7.4.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. France
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Competitive scenario
      • 7.4.4.3. Regulatory framework
      • 7.4.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Italy
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Competitive scenario
      • 7.4.5.3. Regulatory framework
      • 7.4.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Spain
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Competitive scenario
      • 7.4.6.3. Regulatory framework
      • 7.4.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Denmark
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Competitive scenario
      • 7.4.7.3. Regulatory framework
      • 7.4.7.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Sweden
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Competitive scenario
      • 7.4.8.3. Regulatory framework
      • 7.4.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.9. Norway
      • 7.4.9.1. Key country dynamics
      • 7.4.9.2. Competitive scenario
      • 7.4.9.3. Regulatory framework
      • 7.4.9.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Asia Pacific Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Japan
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Competitive scenario
      • 7.5.2.3. Regulatory framework
      • 7.5.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. China
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Competitive scenario
      • 7.5.3.3. Regulatory framework
      • 7.5.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. India
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Competitive scenario
      • 7.5.4.3. Regulatory framework
      • 7.5.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. Australia
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Competitive scenario
      • 7.5.5.3. Regulatory framework
      • 7.5.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. South Korea
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Competitive scenario
      • 7.5.6.3. Regulatory framework
      • 7.5.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.7. Thailand
      • 7.5.7.1. Key country dynamics
      • 7.5.7.2. Competitive scenario
      • 7.5.7.3. Regulatory framework
      • 7.5.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Brazil
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Competitive scenario
      • 7.6.2.3. Regulatory framework
      • 7.6.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Competitive scenario
      • 7.6.3.3. Regulatory framework
      • 7.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. MEA Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Competitive scenario
      • 7.7.2.3. Regulatory framework
      • 7.7.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. Saudi Arabia
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Competitive scenario
      • 7.7.3.3. Regulatory framework
      • 7.7.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. UAE
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Competitive scenario
      • 7.7.4.3. Regulatory framework
      • 7.7.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. Kuwait
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Competitive scenario
      • 7.7.5.3. Regulatory framework
      • 7.7.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Company Market Position Analysis, 2024
  • 8.3. Company Profiles
    • 8.3.1. Charles River Laboratories
      • 8.3.1.1. Company overview
      • 8.3.1.2. Financial performance
      • 8.3.1.3. Service benchmarking
      • 8.3.1.4. Strategic initiatives
    • 8.3.2. The Jackson Laboratory
      • 8.3.2.1. Company overview
      • 8.3.2.2. Financial performance
      • 8.3.2.3. Service benchmarking
      • 8.3.2.4. Strategic initiatives
    • 8.3.3. Crown Bioscience
      • 8.3.3.1. Company overview
      • 8.3.3.2. Financial performance
      • 8.3.3.3. Service benchmarking
      • 8.3.3.4. Strategic initiatives
    • 8.3.4. Altogen Labs
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Service benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Envigo
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Service benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. WuXi AppTec
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Service benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Oncodesign
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Service benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Hera Biolabs
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Service benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. XenTech
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Service benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Abnova Corp.
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Service benchmarking
      • 8.3.10.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
  • Table 4 Global Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
  • Table 5 Global Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
  • Table 6 Global Patient-Derived Xenograft Model Market, by Region, 2018 - 2030 (USD Million)
  • Table 7 North America Patient-Derived Xenograft Model Market, by Country, 2018 - 2030 (USD Million)
  • Table 8 North America Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
  • Table 9 North America Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
  • Table 10 North America Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
  • Table 11 U.S. Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
  • Table 12 U.S. Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
  • Table 13 U.S. Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
  • Table 14 Canada Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
  • Table 15 Canada Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
  • Table 16 Canada Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
  • Table 17 Mexico Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
  • Table 18 Mexico Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
  • Table 19 Mexico Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
  • Table 20 Europe Patient-Derived Xenograft Model Market, by Country, 2018 - 2030 (USD Million)
  • Table 21 Europe Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
  • Table 22 Europe Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
  • Table 23 Europe Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
  • Table 24 Germany Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
  • Table 25 Germany Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
  • Table 26 Germany Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
  • Table 27 UK Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
  • Table 28 UK Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
  • Table 29 UK Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
  • Table 30 France Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
  • Table 31 France Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
  • Table 32 France Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
  • Table 33 Italy Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
  • Table 34 Italy Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
  • Table 35 Italy Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
  • Table 36 Spain Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
  • Table 37 Spain Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
  • Table 38 Spain Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
  • Table 39 Denmark Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
  • Table 40 Denmark Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
  • Table 41 Denmark Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
  • Table 42 Sweden Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
  • Table 43 Sweden Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
  • Table 44 Sweden Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
  • Table 45 Norway Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
  • Table 46 Norway Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
  • Table 47 Norway Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Patient-Derived Xenograft Model Market, by Country, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
  • Table 51 Asia Pacific Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
  • Table 52 China Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
  • Table 53 China Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
  • Table 54 China Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
  • Table 55 Japan Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
  • Table 56 Japan Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
  • Table 57 Japan Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
  • Table 58 India Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
  • Table 59 India Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
  • Table 60 India Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
  • Table 61 South Korea Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
  • Table 62 South Korea Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
  • Table 63 South Korea Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
  • Table 64 Australia Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
  • Table 65 Australia Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
  • Table 66 Australia Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
  • Table 67 Thailand Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
  • Table 68 Thailand Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
  • Table 69 Thailand Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
  • Table 70 Latin America Patient-Derived Xenograft Model Market, by Country, 2018 - 2030 (USD Million)
  • Table 71 Latin America Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
  • Table 72 Latin America Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
  • Table 73 Latin America Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
  • Table 74 Brazil Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
  • Table 75 Brazil Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
  • Table 76 Brazil Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
  • Table 77 Argentina Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
  • Table 78 Argentina Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
  • Table 79 Argentina Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Patient-Derived Xenograft Model Market, by Country, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
  • Table 83 Middle East & Africa Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
  • Table 84 South Africa Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
  • Table 85 South Africa Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
  • Table 86 South Africa Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
  • Table 89 Saudi Arabia Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
  • Table 90 UAE Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
  • Table 91 UAE Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
  • Table 92 UAE Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
  • Table 95 Kuwait Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information Procurement
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Forensic Genomics Market Segmentation
  • Fig. 7 Market Snapshot, 2024
  • Fig. 8 Market Trends & Outlook
  • Fig. 9 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 10 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 11 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 12 Porter's Five Forces Analysis
  • Fig. 13 Global Patient-Derived Xenograft Model Market: Tumor Type Key Takeaways
  • Fig. 14 Global Patient-Derived Xenograft Model Market: Tumor Type Movement Analysis
  • Fig. 15 Global Patient-Derived Xenograft Model Market, for Lung Cancer, 2018 - 2030 (USD Million)
  • Fig. 16 Global Patient-Derived Xenograft Model Market, for Pancreatic Cancer, 2018 - 2030 (USD Million)
  • Fig. 17 Global Patient-Derived Xenograft Model Market, for Prostate Cancer, 2018 - 2030 (USD Million)
  • Fig. 18 Global Patient-Derived Xenograft Model Market, for Breast Cancer, 2018 - 2030 (USD Million)
  • Fig. 19 Global Patient-Derived Xenograft Model Market, for Others, 2018 - 2030 (USD Million)
  • Fig. 20 Global Patient-Derived Xenograft Model Market: Model Type Key Takeaways
  • Fig. 21 Global Patient-Derived Xenograft Model Market: Model Type Movement Analysis
  • Fig. 22 Global Patient-Derived Xenograft Model Market, for Mice Model, 2018 - 2030 (USD Million)
  • Fig. 23 Global Patient-Derived Xenograft Model Market, for Rat Model, 2018 - 2030 (USD Million)
  • Fig. 24 Global Patient-Derived Xenograft Model Market: End Use Key Takeaways
  • Fig. 25 Global Patient-Derived Xenograft Model Market: End Use Movement Analysis
  • Fig. 26 Global Patient-Derived Xenograft Model Market, for Pharmaceutical and Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 27 Global Patient-Derived Xenograft Model Market, for Academic and Research Institutes, 2018 - 2030 (USD Million)
  • Fig. 28 Global Patient-Derived Xenograft Model Market, for A CRO's and CDMO's, 2018 - 2030 (USD Million)
  • Fig. 29 Regional Marketplace: Key Takeaways
  • Fig. 30 Regional Outlook, 2024 & 2030
  • Fig. 31 North America Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
  • Fig. 32 US Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
  • Fig. 33 Canada Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
  • Fig. 34 Mexico Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
  • Fig. 35 Europe Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
  • Fig. 36 Germany Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
  • Fig. 37 UK Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
  • Fig. 38 France Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
  • Fig. 39 Italy Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
  • Fig. 40 Spain Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
  • Fig. 41 Denmark Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
  • Fig. 42 Sweden Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
  • Fig. 43 Norway Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
  • Fig. 43 Asia Pacific Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
  • Fig. 45 Japan Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
  • Fig. 46 China Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
  • Fig. 47 India Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
  • Fig. 48 Australia Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
  • Fig. 49 South Korea Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
  • Fig. 50 Thailand Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
  • Fig. 51 Latin America Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
  • Fig. 52 Brazil Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
  • Fig. 53 Argentina Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
  • Fig. 54 Middle East and Africa Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
  • Fig. 55 South Africa Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
  • Fig. 56 Saudi Arabia Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
  • Fig. 57 UAE Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
  • Fig. 58 Kuwait Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)